News Archives – Page 5 of 15

Replay of the Next Generation Medtech & Device Panel,  8th Annual HealthTech Investment Forum

Pixium Vision is pleased to share the Next Generation Medtech & Device Panel, which took place at 8th Annual HealthTech Investment Forum.

Chaired by:
Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA

Panelists:
Ian Crosbie, CEO, Sequana Medical NV
Jeffrey Scott Cohen, Managing Director, Equity Research, Healthcare & Medical Technologies, Ladenburg Thalmann & Co. Inc.
Jonathan Goldstein, Director, Global Tech Partnerships, Boston Scientific
Lloyd Diamond, President & CEO, PIXIUM VISION SA
Mike Karim, CEO, Oxford Endovascular Ltd.
Rupert Winckler, Head of EMEA Business Development, Olympus Europa SE & Co. KG

Antoine Balavoine2021-11-09T16:31:43+01:00November 9th, 2021|Conferences, News|

Pixium Vision to present at the 3rd edition of Investir Day in Paris, November 2021

Download PDF

Antoine Balavoine2021-11-08T07:46:02+01:00November 8th, 2021|News, Press Releases|

Recording of Lloyd Diamond’s intervention at the OIS EUROPEAN INNOVATION SHOWCASE

Watch the recording

Antoine Balavoine2021-10-22T13:55:53+02:00October 22nd, 2021|Conferences, News|

Presentation on Thursday, October 21, 2021 during 2nd Annual DryAMD Therapeutic Development Summit

Ralf Hornig, Director of Clinical Affairs, presented at the 2nd Annual Dry AMD Therapeutic Development Summit the long-term visual results of the Prima chip in patients with geographic atrophy.

2nd-Annual-Dry-AMD-Therapeutic-Development-Virtual-Event

Listen Ralf Hornig, Director of Clinial Affairs

Download Poster PDF

Download Poster A4 PDF

Antoine Balavoine2021-10-22T09:59:42+02:00October 21st, 2021|Conferences, News|

Edison report of October 20th, 2021 – Three-year data confirms continued Prima safety

« We remain encouraged that there is no degradation in Prima’s prosthetic visual performance, given some external speculation that advanced Dry-AMD could eventually provoke atrophic damage to the retinal ganglion cells (on which the Prima system relies for providing the patient’s prosthetic vision). »

Download PDF

Antoine Balavoine2021-10-20T18:31:43+02:00October 20th, 2021|Broker Research, News|

Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from Prima System French feasibility study

Pixium Vision announces positive long-term data from patients implanted with PRIMA, a state-of-the-art implantable chip. The data were presented at The Eye and The Chip – Virtual Event, held October 3-5, 2021.

PRIMA implant is well tolerated and safe in patients 36 months after implantation
Implant is highly stable with no lifetime deteriorations observed
PRIMA can potentially provide meaningful visual acuity improvement

Download the PDF

Antoine Balavoine2021-10-13T02:53:51+02:00October 13th, 2021|News, Press Releases|

Edison report of October 5th, 2021 – Advancing towards sight restoration in dry-AMD

« While we have pushed back our potential launch forecast to H124 (from H223), after tweaking our market growth assumptions, we now obtain a higher equity valuation of €143.3m (versus €138.0m previously). »

Download PDF

Antoine Balavoine2021-10-07T11:59:21+02:00October 7th, 2021|Broker Research, News|

Pixium Vision to attend the 8th Annual Healthtech Investment Forum on October 5 & 6, 2021

Pixium Vision announces today that the management team will participate in the 8th Annual Healthtech Investment Forum taking place on 5th and 6th of October, 2021, digitally. More information about the event can be found here.

To request one-on-one meeting with Pixium Vision please contact Guillaume van Renterghem at gvanrenterghem@lifesciadvisors.com.

Download PDF

Antoine Balavoine2021-10-04T19:06:55+02:00October 4th, 2021|News, Press Releases|

Implantation of first patient in Germany

Pixium Vision announces the successful first implantation of a patient in Germany in the PRIMAvera pivotal trial.

Successful first implantation of a patient in the PRIMAvera study in Germany
PRIMAvera clinical sites opening in five locations in Germany
Additional clinical sites to open in additional European countries

This follows approval of the PRIMAvera study by Germany’s Federal Institute for Drugs and Medical Devices, which aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. PRIMAvera clinical sites have now opened in Bonn, Sulzbach, Hamburg, Munich and Ludwigshafen with one more in Tuebingen to follow. The PRIMAvera study was initiated in Q4 2020 and the first patient was implanted in March 2021.

Download the PDF

Antoine Balavoine2021-09-23T07:34:31+02:00September 23rd, 2021|News, Press Releases|

Pixium Vision supports La Marche Nationale pour la Vue 2021

More information on IRRP website

Pixium Vision supports LA MARCHE NATIONALE POUR LA VUE which will start in Paris on Saturday, October 9th.

Departure from Place Stalingrad at 2 pm (metro Stalingrad)
Arrival at Place de la Porte de Bagnolet (metro Porte de Bagnolet) around 4:30 pm

A dream walk of about 7 km to support research:
• A bit of canal Saint Martin,
• The Saint-Louis Hospital,
• Belleville Park (it goes up a bit),
• Flirt with Père Lachaise,
• Saint-Germain de Charonne church,
• Porte de Bagnolet

Sign up and come!!!

Antoine Balavoine2021-09-16T17:43:16+02:00September 16th, 2021|News|